Navigation Links
Mylan Launches Paroxetine Hydrochloride Extended-Release Tablets
Date:5/14/2008

PITTSBURGH, May 14 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) today announced that Mylan Pharmaceuticals Inc. has launched Paroxetine Hydrochloride (HCl) Extended-release (ER) Tablets, the generic version of GlaxoSmithKline's (GSK) Paxil CR(R). As the first company to successfully file an abbreviated new drug application (ANDA) containing a paragraph IV certification for the 12.5 mg and 25 mg tablets, Mylan has earned 180 days of marketing exclusivity for these two strengths. Reflecting a supply and distribution agreement with GSK, Mylan also has the right to market the 37.5 mg strength. Mylan is not aware of any other ANDA filers with paragraph IV certifications for this product.

"As another first-to-file opportunity, Paroxetine HCl ER reflects Mylan's continued dynamic speed-to-market capabilities," says Robert J. Coury, Mylan's vice chairman and CEO. "Because this product also belongs in the 'difficult- to-manufacture' category, it is yet another example of our historically strong R&D process, through which we're able to deliver affordable versions of important complex therapies. Our settlement with GSK is consistent with our commitment to monetize opportunities when it benefits both patients and our shareholders."

Paroxetine HCl ER Tablets had U.S. sales of approximately $301 million for the 12 months ending March 31, 2008, for all three strengths.

In October 2007, Mylan announced the settlement of patent litigation involving Paroxetine HCl ER. At that time, Mylan stated that the settlement would provide the company with patent licenses and the right to market all three strengths beginning no later than Oct. 1, 2008. As part of the settlement agreement, which remains confidential, Mylan has been provided with
'/>"/>

SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Mylan Schedules Financial Results Conference Call and Live Webcast for the First Quarter Fiscal 2008
2. Mylan Declares Quarterly Preferred Stock Dividend
3. Mylan Appoints Michael J. Monroe Senior Vice President for Global Public Affairs
4. Mylan Announces Final FDA Approval for Trandolapril Tablets
5. Mylan Announces Final FDA Approval for Felodipine Extended-Release Tablets, USP
6. Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter
7. Mylan Announces Appointment of Jagdish Dore as CEO and Managing Director of Matrix Laboratories
8. Mylan Revises Timing of Its Financial Results Conference Call for the Quarter and Nine Months Ended Dec. 31, 2007, to 5 p.m. ET
9. Mylan Confirms Its Matrix Design Fentanyl Patch Is Not Included In the Widespread Recall Announced February 12th
10. Mylan Restores Availability of Generic Levothyroxine in Florida
11. Mylan Schedules Financial Results Conference Call and Live Webcast for the Quarter and Nine Months Ended Dec. 31, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2014)... Australian researchers reveal that sudden, acute episodes of low ... as temperature, humidity, air pressure, wind direction and precipitation. ... a journal of the American College of Rheumatology (ACR), ... increases with higher wind speed or wind gusts, but ... World Health Organization (WHO) nearly everyone experiences low back ...
(Date:7/9/2014)... School of Medicine at the University of Pennsylvania in ... an $8 million grant from the National Cancer Institute ... (PDT) in patients with malignant pleural mesothelioma, a rare, ... in the lining of the lungs and is caused ... fund a clinical trial and additional studies looking at ...
(Date:7/9/2014)... that captures heretofore hidden ways that cells are regulated, ... makes breast cancer cells more likely to metastasize. , ... in part by blocking two other proteins that are ... two disease processes could have unexpected ties. , ... of Nature , points to the possibility of ...
(Date:7/9/2014)... Center paint a relatively optimistic picture of women,s chances ... spread to the chest wall or skin, but not ... regardless of size and whether they have involved lymph ... called "locally advanced" tumors, suggesting that they are a ... Locally advanced breast cancers of this and other types ...
(Date:7/9/2014)... The Miriam Hospital have found that people with ... depressed have difficulty sticking to a pulmonary rehabilitation ... women, and screening and brief treatment of depression ... study and its findings are published in print ... obstructive pulmonary disease is a common and often ...
Breaking Medicine News(10 mins):Health News:Low back pain? Don't blame the weather 2Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Protein pushes breast cancer cells to metastasize 2Health News:Protein pushes breast cancer cells to metastasize 3Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3Health News:Miriam Hospital study examines effect of depressed mood on pulmonary rehab completion 2
... Ph.D., a senior research scientist in the Department of ... Park, has been chosen to receive a 2009 Astellas ... Chemical Society, is given to individuals who have made ... their work in the chemical and related sciences. ...
... ... Carestream Health will Share Insights and Best Practices for Developing an Intelligent Portfolio ... Austin, Texas ... management solutions, will host a case study webinar discussing best practices for increasing ...
... , U.S. Rep. ... , WASHINGTON, Dec. 10 The Federal Employees Health Benefits ... American Federation of Government Employees, (AFGE) "Inside Government" radio program. The ... on Federal News Radio at www.federalnewsradio.com ...
... Speaker Nancy Pelosi issued the following statement today applauding ... Appropriations Act lifting the ban on federal funding for syringe ... bill passed the House this afternoon by a vote of ... syringe exchange could not be more clear. As Dr. Anthony ...
... Savient Pharmaceuticals, Inc. (Nasdaq: SVNT ) today announced that ... Morgan Healthcare Conference on Monday, January 11, 2010 at 2:30 p.m. ... Francis Hotel in San Francisco, CA. , Individuals can ... section of the company,s web site www.savient.com . Following ...
... may help avert drug errors, study authors suggest, , ... finds that even adults who know what medicines they ... getting in the hospital. , Forty-four percent of patients ... that was not actually prescribed. A patient who normally ...
Cached Medicine News:Health News:Planview and Carestream Health Discuss the Intelligent Portfolio on December 17 Webinar 2Health News:Planview and Carestream Health Discuss the Intelligent Portfolio on December 17 Webinar 3Health News:FEHBP Open Enrollment Period to be Discussed on Special Rebroadcast of 'Inside Government' 2Health News:Pelosi: Lifting the Ban on Federal Funding for Syringe Exchange is a Victory for Science and for Public Health 2Health News:Most Hospital Patients Don't Know What Meds They're Taking 2Health News:Most Hospital Patients Don't Know What Meds They're Taking 3
(Date:1/14/2014)... /PRNewswire-iReach/ -- Acumed,s new SLIC Screw System - a ... to place and insert the screw accurately - offers ... ligament) repair or reconstruction as it holds the bones ... http://photos.prnewswire.com/prnh/20140114/MN45636 ) The SLIC Screw ...
(Date:1/14/2014)... 2014   NuAire , a manufacturer of ergonomically designed laboratory ... Koki of Japan to sell and ... . NuAire will utilize its network of sales professionals throughout ... to offer assistance in application use, product benefits and ...
(Date:1/14/2014)... N.Y. , Jan. 14, 2014   Oligomerix, Inc. , ... modifying therapeutics for Alzheimer,s disease (AD) and related neurodegenerative ... to Valhalla, NY as of ... laboratory space at New York Medical College. ...
Breaking Medicine Technology:Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3NuAire announces sales and service of Hitachi Koki centrifuges in North America 2Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... senior health policy analyst for Consumers Union, will urge Congress ... before the House Energy & Commerce Health Subcommittee.  The ... of the Medical Device User Fee Act beginning at 10:15 ... Recent safety problems with metal hip implants ...
... LA JOLLA, Calif., Feb. 15, 2012 Celladon ... and development of innovative treatments for cardiovascular diseases, ... million equity financing to advance its lead investigational ... failure. The financing was led by new investor ...
Cached Medicine Technology:Consumers Union to Testify for Stronger Medical Device Safety Oversight at House Hearing Today 2Consumers Union to Testify for Stronger Medical Device Safety Oversight at House Hearing Today 3Celladon Corporation Completes $43 Million Financing to Advance MYDICAR® for the Treatment of Heart Failure 2Celladon Corporation Completes $43 Million Financing to Advance MYDICAR® for the Treatment of Heart Failure 3
... Delivers the advanced performance benefits ... strength, versatility, and durability ... that augments the effectiveness of ... floor reconstruction. Comprised of sterile, ...
... (also known as the VOCARE) Bladder System ... used by people with spinal cord injuries ... demand. A secondary use of the device ... promote penile erection.,The Bladder System includes surgically ...
Used for dilation of a tract to the kidney for removal of stones. Supplied sterile in peel-open packages. Intended for one-time use....
... Urinary Control offers a revolutionary approach ... symptoms of overactive bladder, including urinary ... urgency-frequency alone or in combination in ... not tolerate more conservative treatments. Medtronic ...
Medicine Products: